Floatz logo

Nivolumab

Ureter Transitional Cell Carcinoma

Explore 15 assets in Ureter Transitional Cell Carcinoma →
Floatz Rating
BB68/100
Confidence
Indicative
v0.2
Sponsor
Alliance for Clinical Trials in Oncology
Modality
monoclonal_antibody
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
57Moderate confidence
Detailed axis rationale is planned and will be published soon.
TrialPhaseStatusNPrimary endpointReadout
NCT05987241CT.gov
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
—Recruiting———
NCT04637594CT.gov
Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy
—Active Not Recruiting———
NCT04940299CT.gov
Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma
—Active Not Recruiting———
NCT04953104CT.gov
ARID1A and/or KDM6A Mutation and CXCL13 Expression
—Active Not Recruiting———
NCT04848519CT.gov
Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma
—Active Not Recruiting———
NCT03606174CT.gov
A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma
—Terminated———
NCT02496208CT.gov
Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors
—Active Not Recruiting———

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.

Same indication · Ureter Transitional Cell Carcinoma

AssetSponsorPhaseRating
Nivolumab (this asset)Alliance for Clinical Trials in OncologyP3BB · 68
CyclophosphamideFred Hutchinson Cancer CenterP3BB
Enfortumab Vedotin (Fully Human Monoclonal Antibody Conjugated To A Cytotoxic Agent Monomethyl Auristatin E (Mmae) Targeting Nectin-4)Fred Hutchinson Cancer CenterP2BB
PembrolizumabFred Hutchinson Cancer CenterP3BB
Cis-Diamminedichloroplatinum IiNational Cancer Institute (NCI)P3B
AtezolizumabAlliance for Clinical Trials in OncologyP3B
RelatlimabM.D. Anderson Cancer CenterP2B
DurvalumabAlliance for Clinical Trials in OncologyP3B
IpilimumabM.D. Anderson Cancer CenterP2B

+11 more in the Ureter Transitional Cell Carcinoma cohort

Other indications for Nivolumab

IndicationSponsorPhaseRating
Renal Carcinoma—P4BBB · 72
Metastatic Melanoma—P4BB · 70
Non-Small Cell Lung Carcinoma—P4BB · 70

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Related assets

Citation

Floatz Terminal. Nivolumab in Ureter Transitional Cell Carcinoma. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026.
Accessed July 14, 2026.
https://terminal.floatz.ai/assets/nivolumab-ureter-transitional-cell-carcinoma

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →